Skip to main content
SpringerLink
Log in

Preliminary data on the efficacy of a new human menopausal gonadotropin (hMG) preparation containing a reduced amount of luteinizing hormone (LH) for superovulation in an in vitro fertilization (IVF) program

  • Short Communications
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hillier SG: Ovarian manipulation with pure gonadotrophins. J Endocrinol 1990;127:1–6

    Google Scholar 

  2. Howles CM, McNamee MC, Edwards RG: Follicular development and early luteal function of conceptional and nonconceptional cycles after human in-vitro fertilisation: Endocrine correlates. Hum Reprod 1987;2:17–21

    Google Scholar 

  3. Antoine JM, Salat-Baroux J, Alvarez S, Cornet D, Tibi C, Mandelbaum J, Plachot M: Ovarian stimulation using human menopausal gonadotrophins with or without LHRH analogues in a long protocol for in-vitro fertilization: A prospective randomized comparison. Hum Reprod 1990;5:565–569

    Google Scholar 

  4. Bernardus RE, Jones GS, Acosta AA, Garcia JE, Liu HC, Jones DL, Rozenwaks Z: The significance of the ratio in FSH and LH in induction of multiple follicle growth. Fertil Steril 1985;43:373–378

    Google Scholar 

  5. Navot D, Rozenwaks Z: The use of follicle-stimulating hormone for controlled ovarian hyperstimulation in in vitro fertilisation. J Vitro Fert Embryo Transfer 1988;5:3–13

    Google Scholar 

  6. Edelstein MC, Brzyski RG, Hones GS: Equivalency of human menopausal gonadotropin and follicle-stimulating hormone stimulation after gonadotropin-releasing hormone agonist suppression. Fertil Steril 1990;53:475–481

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynaecology and Biology of Reproduction, Service Pr Salat-Baroux Hôpital Tenon, 4 rue de la Chine, 70520, Paris, France

    J. M. Antoine, J. Salat-Baroux, S. Alvarez, D. Cornet & C. Tibi

  2. Laboratories Serono SA, Boulogne, France

    V. Brieu

  3. Unité 173 INSERM Hôpital Necker, Paris, France

    J. Mandelbaum & M. Plachot

Authors
  1. J. M. Antoine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Salat-Baroux
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Alvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Cornet
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Tibi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. Brieu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Mandelbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Plachot
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Antoine, J.M., Salat-Baroux, J., Alvarez, S. et al. Preliminary data on the efficacy of a new human menopausal gonadotropin (hMG) preparation containing a reduced amount of luteinizing hormone (LH) for superovulation in an in vitro fertilization (IVF) program. J Assist Reprod Genet 9, 404–406 (1992). https://doi.org/10.1007/BF01203968

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01203968

Keywords

Search

Navigation